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Abstract. Increasing resistance of Plasmodium falciparum malaria to antimalarial drugs is posing a major threat to
the global effort to “Roll Back Malaria”. Chloroquine and sulfadoxine-pyrimethamine (SP) are being rendered increas-
ingly ineffective, resulting in increasing morbidity, mortality, and economic and social costs. One strategy advocated for
delaying the development of resistance to the remaining armory of effective drugs is the wide-scale deployment of
artemisinin-based combination therapy. However, the cost of these combinations are higher than most of the currently
used monotherapies and alternative non-artemisinin−based combinations. In addition, uncertainty about the actual
impact in real-life settings has made them a controversial choice for first-line treatment. The difficulties in measuring the
burden of drug resistance and predicting the impact of strategies aimed at its reduction are outlined, and a mathematical
model is introduced that is being designed to address these issues and to clarify policy options.
INTRODUCTION
The aim of this report is to provide an overview of antima-
larial drug resistance with a particular emphasis on the place
of artemisinin-based combination therapy (ACT) in the re-
duction of the burden of malaria. The difficulties in measur-
ing the burden of drug resistance and predicting the impact of
strategies aimed at its reduction are outlined. We aim to dem-
onstrate how a bioeconomic model might be developed and
deployed to address these issues and to clarify policy options.
Antimalarial drug resistance is now generally acknowl-
edged to be one of the greatest threats to our ability to “Roll
Back Malaria.”1,2 The situation is worsening, with the geo-
graphic spread of resistance widening to previously unaf-
fected areas and a remorseless increase both in the prevalence
and degree of drug resistance. Chloroquine-resistant Plasmo-
dium falciparum now predominates in Southeast Asia, South
America, and increasingly in Africa. Resistance to sulfadox-
ine-pyrimethamine (SP) is widespread in Asia and South
America and is spreading in Africa.3,4 Chloroquine and SP
are affordable drugs at approximately US$0.10−0.20 per adult
course, and their safety and efficacy as oral regimens means
they have generally been readily accessible. When parasites
began to show resistance to these drugs in Southeast Asia, the
epicenter for multidrug-resistant P. falciparum malaria, they
had to be replaced by the more expensive mefloquine. How-
ever, resistance soon developed to this compound, with resis-
tance first being noted only six years after it was first de-
ployed in Thailand in 1984, and spreading quickly thereafter.
The efficacy of halofantrine, which shares cross-resistance
with mefloquine, also decreased and even quinine has gradu-
ally become less effective over time (Figure 1).
Resistance to affordable drugs in Africa, which carries an
estimated 90% of the burden of malaria, has reached critical
levels. The continent faces the crucial issue of which drug
regimen to switch to and when to make a switch. There is
increasing acceptance that the ideal approach to antimalarial
treatment is to use a combination of two or more drugs rather,
than a single antimalarial drug, preferably with an artemisinin
derivative as one of the partner drugs.5 However, ACTs
are relatively expensive, currently costing approximately
US$1.20−3.50 per adult course. In addition, concerns about
the practical difficulties in implementing any change in policy
and the uncertainties about future costs, risks, and benefits,
all make the decision of whether to switch, when to switch,
and what drug regimen to switch to, a complex one.6−8 In
order for national governments, donor countries, and inter-
national institutions to make rational decisions on drug
policy, there is a need to clarify how much of a burden anti-
malarial resistance causes currently, how much it is likely to
cause in the future under different control strategies, and how
much these strategies will cost and save.
Models are increasingly being used to help explore policy
options such as these, where outcomes are uncertain and de-
cisions complex.9,10 They are ideally suited to exploring both
biologic and economic influences on outcomes. Moreover,
they can be used to produce the estimates of the cost-
effectiveness of policy options which are now accepted to be
a vital input to decision making in the health sector.11,12
ANTIMALARIAL DRUG RESISTANCE–
THE BURDEN
The nature of the burden. The burden of disease caused by
malaria and its consequences has been documented in terms
of childhood mortality,13 anemia,14 maternal and infant mor-
bidity and mortality,15 neurologic disability,16,17 and eco-
nomic and social costs.18,19 The burden caused specifically by
antimalarial drug resistance is more difficult to quantify.20
Recent estimates based on the best available data from Africa
suggest that the demise of chloroquine is the “most plausible
single factor contributing to the change in malaria specific
mortality,”21 which has been estimated to have at least
doubled over the last 15 years.22
The actual relationships between therapeutic response to
treatment and ex vivo measures such as resistance in vitro and
the carriage of resistance genes is generally poorly defined,
but of the drug, parasite, and host factors that contribute to
therapeutic outcome, particularly important is the immunity
of the host. Thus, in areas of high transmission, adults are
relatively immune and tend to self cure irrespective of the
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effectiveness of the drug or indeed whether an antimalarial
drug is taken at all. Everyone has malaria parasites in their
blood all the time, but usually at densities below that causing
illness. The sensitivity of the parasite to the drug affects the
clinical outcome more noticeably where the hosts are non-
immune and unable to control the infection themselves (i.e.,
patients of all ages in low transmission areas or young chil-
dren in high transmission areas). In these circumstances, tak-
ing an ineffective drug can result in severe or protracted dis-
ease and even death. If an effective second-line drug is easily
accessible, this impact may be limited although costs, particu-
larly to the patient, may increase.23 Unfortunately, however,
effective second line drugs are often not readily available and
therefore first line drug failure can lead directly to an increase
in morbidity and mortality.
The burden of antimalarial drug resistance in terms of in-
creased costs includes the direct cost of more expensive sec-
ond- or third-line treatments and hospital admissions, the
costs of seeking treatment, and the indirect costs of lost pro-
ductivity.18 In addition, there are broader costs at the house-
hold and macroeconomic levels19 as well as intangible costs
such as psychological stress and loss of confidence in a health
system that fails to deliver a cure. Much of this burden falls on
the poor, exacerbating already existing inequities, since the
more expensive, effective antimalarials are accessible only to
patients affluent enough to obtain them through informal
sources, and remain out of reach to the majority of the rural
poor who carry the largest burden of disease.
Measuring the burden. Measuring the impact of antima-
larial drug resistance is difficult, and the impact may not be
recognized until it is severe, especially in high transmission
areas.24 This is partly because routine health information sys-
tems grossly underestimate the magnitude of the problem.25
Until the prevalent malaria parasites become completely re-
sistant, patients will usually have an initial response to the
drug, with a reduction in parasite numbers. However, as drug
levels fall below the minimum inhibitory levels of the infect-
ing resistant parasite in the individual patient, the parasite
population once again begins to expand. By the time the para-
site biomass increases back to a level causing symptoms, and
is microscopically detectable, several days or weeks may have
passed and the symptoms may not be associated with the
initial illness, by either the patient or the health worker, and
as a consequence may not be recorded as a treatment failure.
This lack of reliable information is exacerbated by the fact
that in many settings the majority of patients with malaria
symptoms do not access the public sector where such infor-
mation can be collected.26
Since routine health information systems cannot often be
relied upon for accurate data on drug efficacy, there is a need
for systematic surveillance and monitoring. Much effort has
recently been put into setting up national and regional net-
works that use standardized methodology for monitoring in
vivo drug efficacy.27−29 In recent years, there has been a trend
towards 14-day assessments in high transmission areas. Ide-
ally, follow-up should be for at least 28 days, since failures do
not become apparent within 14 days of taking treatment until
drug resistance has reached very high levels and following
patients up only until the 14th day results in a serious over-
estimation of the efficacy of failing drugs.30 One of the argu-
ments for the 14-day test was the difficulty in differentiating
between recrudescence and reinfection, especially in areas of
high transmission. Now that the genotypes of parasites in
initial infections can be compared with those in any subse-
quent infections and it is therefore possible to differentiate
confidently between reinfections and recrudescent infections,
longer follow-up studies can and should be undertaken.
Reducing the burden. In considering possible strategies for
the reduction of the burden of antimalarial drug resistance, it
is useful to differentiate between the current burden of drug
resistance and the potential burden in the future resulting
from the continued emergence and spread of drug resistance.
Central to achieving a reduction in both current and future
burdens is an improvement in drug usage by patients and
providers so that good quality drugs are available and taken
at the correct dose and for a sufficient length of time to affect
a radical cure and reduce the likelihood that partially resistant
parasites will survive.
Improving drug use is most effective where the parasite is
still sensitive to the drug. Where resistance has rendered the
drug ineffective, the current burden of resistance can only be
reduced by replacing the failing drug regimen with one that is
effective. The difficulty lies in deciding which drug regimen to
switch to, since the choice of drug or drug combination will
determine the subsequent development of drug resistance.
Reducing the future burden of resistance requires that ef-
fective antimalarial drugs continue to be available in the fu-
ture and requires the continuous search for and development
of potential new antimalarial drugs31,32 (http://www.mmv.
org). However, the complete drug development process can
take 10−15 years, making it imperative that the currently
available drugs are deployed in a way most likely to maximize
their lifespan by decreasing the likelihood that resistance will
develop. The key strategy put forward to do this is to use
available drugs in combination to prevent the emergence and
spread of resistance.
THE EMERGENCE AND SPREAD OF
ANTIMALARIAL DRUG RESISTANCE
The emergence of antimalarial drug resistance is dependent
on the occurrence of a spontaneous genetic change (mutation
or gene amplification) in a malaria parasite, which interferes
with that parasite’s susceptibility to a drug. A single mutation
may be sufficient to confer almost complete resistance to
FIGURE 1. Drug efficacy in western Thailand. CQ chloroquine;
SP sulfadoxine-pyrimethamine; Q  quinine; QT  quinine and
tetracycline; M15  mefloquine, 15 mg/kg; M25  mefloquine, 25
mg/kg.
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some drugs (e.g., atovaquone) or more usually there is a se-
ries of mutations that confer increasing tolerance of the para-
site to increasing drug concentrations, as in the cases of py-
rimethamine and chloroquine.33
However, for resistance to spread, the spontaneous occur-
rence of a mutation in itself is not sufficient. In the absence of
the drug to which it is potentially resistant, a parasite with the
resistant mutation does not have a survival advantage and
therefore does not reproduce faster than the non-mutants.
There may even be a survival disadvantage, a so-called fitness
cost to having the mutation.34 In the presence of the particu-
lar drug, the multiplication of the sensitive parasites is inhib-
ited allowing the drug-resistant mutants to survive and mul-
tiply (i.e., selection), increasing the likelihood of transmission
to the next host and therefore the spread of resistance.
Strategies for preventing spread. Once a drug-resistant mu-
tant has arisen, preventing spread of resistance is difficult.
Spread is facilitated by the exposure of malarial parasites to
sub-therapeutic levels of antimalarial drugs, that kill sensitive
parasites but allows parasites with a resistance mutation to
survive and reproduce. Ensuring that drugs are taken in at a
sufficient dose and for a sufficient duration reduces this risk.
Drug pressure is higher where a drug with a long half-life is
taken because the drug remains in the patient’s blood at low
levels for weeks, exposing any newly introduced malarial
parasites to sub-therapeutic levels.35 This is particularly likely
to occur in high transmission areas where people are not only
infected more frequently, but also take antimalarial drugs
frequently whether or not they are have malaria. Theoreti-
cally, this form of drug pressure can be reduced by using drugs
with a shorter half-life and by restricting the use of the first-
line drug to patients with confirmed malaria: i.e., only treating
those with a definitive diagnosis. There are downsides to both
of these strategies that pit the long-term public health benefit
against the benefit to the individual patient. Using drugs with
short half-lives such as artesunate means that if they are used
together with other rapidly eliminated drugs they need to be
taken for a longer period resulting in poorer patient adher-
ence and less likelihood of cure compared with drugs with
longer half-lives such as mefloquine or SP, which can be taken
over a three-day period or in a single dose. However, in com-
bination with another effective drug, ACTs only require three
days of treatment. Restricting usage of effective drugs to pa-
tients who have a definitive diagnosis of malaria would reduce
access to cure to the most vulnerable communities because
the availability and reach of diagnostic facilities is so poor.
This would be expected to lead to an increase in current
morbidity and mortality, a trade-off between current and fu-
ture burden of disease, which is clearly unacceptable.
The use of rapid diagnostic tests that require minimal train-
ing and equipment may be a potential solution.20 However,
their cost of US $0.7 per test and the high levels of asymp-
tomatic parasitemia and therefore false-positive results in ar-
eas of high transmission, limit the appropriateness of this
technology to lower transmission areas. The cost-effective-
ess of the diagnostic tests depends on their cost relative to
that of the ACT and the positive predictive value of clinical
diagnosis. For example, they are unlikely to be cost-effective
when more than 50% of the patient group with a clinical
diagnosis of malaria indeed does have an infection.
Strategies for preventing emergence. Because it is difficult
to control antimalarial drug resistance once it has emerged,
there is a need for strategies that prevent the rare event of
initial emergence. Combinations of drugs which have differ-
ent molecular targets delay the emergence of resistance. How-
ever, malaria control programs may be reluctant to adopt this
strategy because until resistance emerges, there is no evident
benefit to the more expensive combination treatment.
ARTEMISININ-BASED COMBINATION THERAPY
The rationale. The rationale for using drugs in combination
is well established in the treatment of tuberculosis, infection
with human immunodeficiency virus, and cancer. The prob-
ability of a parasite arising that is resistant simultaneously to
two drugs with unrelated modes of action is the product of the
per parasite mutation frequencies multiplied by the total
number of parasites exposed to drugs.36 Therefore, if the
probability of a parasite being resistant to drug A is one in 109
and to drug B is one in 109 then the probability that a parasite
will be simultaneously resistant to both is one in 1018, repre-
senting a billion-fold reduction in probability. Mutations con-
ferring resistance to artemisinins have never been docu-
mented and are therefore much less likely to occur than mu-
tations to some other drugs such as SP.
Artemisinins are a particularly effective partner drug be-
cause they are more active than any other antimalarial, re-
ducing the number of parasites by approximately 104 per
asexual cycle36 and therefore reducing the number of para-
sites that are exposed to the partner drug alone. In addition,
artemisinins have broad stage specificity and can be used to
treat severe as well as uncomplicated malaria. They inhibit
the production of gametocytes and therefore have a potential
to reduce transmission37 and finally, to date, there has been
no evidence of stable resistance either in therapeutic use or in
experimental systems.
Artemisinins taken on their own as monotherapy must be
taken for seven days for radical cure. However, adherence to
seven-day regimens is extremely low and a three-day regimen
is generally regarded as the maximum because most people
discontinue treatment when they feel better usually after a
couple of days, and this can result in late recrudescences with
monotherapy. Used in combination with another effective
drug, a three-day course is sufficient and better adhered to
and has the important advantage of protecting these valuable
drugs.38
The evidence. There is an increasing body of field evidence
supporting the theoretical basis for ACTs, principally from
the Thailand-Myanmar border and more recently from South
Africa. In an area on the Thailand-Myanmar border, the
widespread deployment of ACT was associated with a de-
creased incidence in malaria,39 sustained effectiveness of the
combination for more than 10 years, and an increase in me-
floquine sensitivity in vitro.40 These results were obtained
despite artesunate being added to mefloquine when resis-
tance to the latter was already widespread, a less than ideal
scenario in terms of delaying antimalarial resistance. In Kwa-
Zulu-Natal in South Africa, the combined effect of switching
from SP to the fixed combination of artemether-lumefantrine
and residual spraying with DDT was associated with a de-
crease in cases of 78% and an increase in cure rate of 87%
(Barnes K, unpublished data).
The argument against using ACTs. There are a number of
concerns about widespread deployment of ACT,41 the chief
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one being cost. These combination therapies currently cost
more than US$1 for an adult course (although this cost is
decreasing), so for them to be widely deployed as first-line
therapy, substantial subsidy will be required to ensure that
they are available to everyone, including those who cannot
afford the market price. A second concern is that by deploy-
ing the artemisinin derivatives now, we risk losing our most
valuable antimalarial, a potentially catastrophic event. This is
particularly a concern in many tropical country settings be-
cause the local capacity to deliver health care to the popula-
tion is often inadequate, in part due to a chronic lack of
resources. Under these circumstances, implementing a change
in drug policy without addressing underlying problems with
delivery is likely to result in low rates of coverage and the
inappropriate use of the drugs.
Currently there is only one registered co-formulated ACT
that is produced to internationally recognized good manufac-
turing practice standards; artemether-lumefantrine (Co-
Artem; Novartis International AG, Basel, Switzerland). This
has the disadvantage of requiring a twice a day dose and
needing to be taken with fat to ensure adequate absorption.
Recently, a co-formulated product of dihydroartemisinin-
piperaquine (Artekin; Holleykin Pharmaceutical Co., Ltd.,
Guangzhou, Guandong, People’s Republic of China) has
been shown to be safe, effective, and acceptable in clinical
trials.42 It is currently available at about half the cost of ar-
temether-lumefantrine in Cambodia, China, and Vietnam
where it has been used extensively. However, the current
product has not yet undergone the lengthy and costly regu-
latory process required for international approval, and it will
therefore be several years before it can be more widely de-
ployed unless this process can be hastened. Fixed artesunate-
mefloquine and artesunate-amodiaquine co-formulated drugs
are under development.
If any other artemisinin-based combination is used today,
such as artesunate and mefloquine or artesunate and SP, then
it must be given as two separate types of tablets and there is
a risk that patients will take only the artemisinin derivative
responsible for rapid symptom resolution and that this will
only be taken for a few days. Not only will this result in
treatment failures, but also it theoretically increases the risk
of drug resistance emerging in the future. Specific strategies
aimed at improving coverage and correct drug usage can go
some ways to addressing these concerns, including blister
packaging of drugs43 and involvement of the informal sector
in providing treatment.44
The policy dilemma. However, because of the costs, risks
and uncertainties involved in switching to artemether-
lumefantrine or a non−co-formulated ACT now, many coun-
tries are delaying the decision or choosing an interim option
such as SP on its own, or a combination of two non-
artemisinin drugs such as chloroquine and SP. Often this is
already ineffective, or the likelihood is that it will only remain
effective for a few years before drug resistance worsens fur-
ther (as the components are available individually) rendering
the combination ineffective. So in making this choice, it is
assumed or hoped that an affordable co-formulated ACT will
become available in the near future. Apart from concerns
over efficacy, a disadvantage of such an approach is that it
may result in two changes in drug policy within a potentially
short space of time. Not only does each change require a
major investment of scarce human and financial resources,
but frequent policy change is likely to lead to confusion
among the public and a loss of credibility of the policy mak-
ers.
In the meantime, artemisinins are already increasingly
available and are being used on their own as monotherapy,
especially in the informal sector, which is often a community’s
main source of treatment. For example, in Cambodia a recent
survey showed that more than 80% of the patients with a
malaria-like illness sought treatment in the informal sector
where 37% of the antimalarials treatments obtained con-
tained an artemisinin, but of these only 20% of these were
taken in combination with mefloquine as recommended.
(Yeung SM, unpublished data). This use of artemisinin de-
rivatives as monotherapy is a major threat to the ACT strat-
egy and the challenge is therefore to make sure that they are
deployed in a way that is least likely to encourage the devel-
opment of resistance by ensuring that they are always used in
combination with another effective anti-malarial drug.
The policy implications of these potential risks and benefits
are the subject of intense debate. Clearly, the decision of
when to switch and what to switch to is a complex one. Many
scientific, behavioral, economic, and political factors need to
be taken into consideration. Within all of these areas, many
uncertainties remain in key areas. To clarify these issues, we
are developing a bioeconomic model of antimalarial drug re-
sistance and combination therapy. The aim is to use the model
for a cost-benefit analysis to explore the implications of policy
decisions such as the timing of switches in relation to the
existing levels of drug resistance, the coverage achieved by
the policy change, and specific strategies aimed at increasing
coverage. At the core of the overall model is a biologic model
of the transmission of antimalarial drug resistance.
MODELING ANTIMALARIAL DRUG RESISTANCE
The model of anti-malarial resistance aims to describe ma-
laria epidemiology and predict the effect of potential policy
interventions based on sound representations of the underly-
ing biology. The predictions in terms of the prevalence of
malaria infections and the proportion of infections that are
resistant are used to calculate future cost and effectiveness.
Previous mathematical models in malaria have tended to
focus on intra-host dynamics, epidemiology, or drug resis-
tance in isolation.45−53 A more recent model by Hastings and
others35 explores the effect of pharmacokinetic and pharma-
codynamic properties on resistance and allows resistance to
evolve more realistically through gradually increasing drug
tolerance. In this current model of antimalarial drug resis-
tance, we aim to incorporate drug, epidemiologic, parasito-
logic, vectorial, host, behavioral, and economic factors based
on available data.
Model outline. The model is a time iterative model where
resistance occurs and develops in two stages as mentioned
above: de novo emergence and spread. The model used
throughout this paper focuses only on the spread of resis-
tance, allowing assumptions about the emergence of resis-
tance for different drugs and drug combinations to be speci-
fied or explored in more detail in a preceding emergence
model that incorporates mutation or amplification frequen-
cies and factors (such as immunity) likely to reduce per para-
site probabilities of survival.
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To start the model, a set of initial inputs is required. These
inputs are described later in this report. The iteration starts
with a population of humans with a specified total frequency
of infections and a proportion of resistant infections. It is
assumed that a single resistant parasite is capable of expand-
ing and cause a resistant infection in the host and that this can
be transmitted resulting in one or more resistant infections in
the next iteration. Transmission occurs at random within the
human host population and at the end of each iteration the
total number of infections and the ratio of resistant and sen-
sitive infections are obtained. These intermediate outputs are
then fed back into the model so that the next iteration of the
model is run with the updated infection frequencies and the
updated immunity profile, which is described later in this re-
port. The process is repeated until the user-defined time limit
is reached, eradication is achieved, or resistance reaches
100% (Figure 2).
Immunity. Central to the model is the effect of host immu-
nity on the fate of an inoculated infection, its subsequent
transmission, and the development of resistance. The effects
of immunity included in the model are a reduction in parasite
density,54 a reduction in the proportion of infections that are
symptomatic,55 an increase in likelihood of self cure and cure
rate of treated infections,56 and a reduction in the reproduc-
tive rate (due to a decrease in duration of infection and treat-
ment failure).57,58
Host immunity affects the development of drug resistance
in a number of ways, including a direct influence on the like-
lihood that an infected person will be symptomatic and will
therefore seek treatment. The relationship between an over-
simplified binary description of immunity (fully immune and
fully non-immune) and the proportion of patients treated in a
low and high transmission intensity area is shown in Figure 3.
In a low transmission area (i.e., an entomologic inoculation
rate [EIR] < 3), the level of immunity in the population is low
and therefore the majority of patients will be symptomatic
and seek treatment when they are infected with malaria. In
contrast, in high transmission areas, the high level of immu-
nity means the majority of the patients who are parasitemic
are asymptomatic and therefore proportionally fewer of them
seek treatment, exposing proportionally fewer parasites to
drugs (although quantitatively there are more infected pa-
tients than in low transmission areas). In this situation, the
selective pressure is lower because the transmission advan-
tage of resistant infections is diluted by transmission from
asymptomatic gametocyte carriers.
If patients are treated they can receive either combination
therapy (CT) or monotherapy using one of the drugs in the
combination (non-CT). In each population, transmission oc-
curs both within and across the groups. Transmission is quan-
tified by the basic reproductive rates (R0). For sensitive in-
fections, the reproductive rate is lower in treated infections
than in untreated infections and lowest if the treatment re-
ceived is an artemisinin-based CT. The rate of spread of re-
sistance is determined by the ratio of the reproductive rates of
the resistant infections compared with sensitive infections in
each of the treatment groups. Initially, a relative reproductive
rate of 4 for sensitive compared with resistant infections was
used. This comes from a study37 that showed that patients
who had treatment failures following mefloquine carried ga-
metocytes four times longer than patients with sensitive in-
fections.
Incorporating immunity into the model. The mode of ac-
quisition of immunity is complex and uncertain and whether
age affects the rate of acquisition of immunity independent of
malaria exposure is still questioned.59,60 However, to make
the model realistic, a function is required to incorporate the
effects of infection frequency on immunity and the effects of
changes in immunity need to be fed back into the model. In
order to do this, immunity functions were constructed based
on age stratified rates of parasitaemia, parasite density ma-
laria morbidity and severe malaria at different transmission
intensities. These functions are used at each iteration of the
model to determine the parasite density, proportion of
treated and non-treated infections, and the reproductive rates
of each age group in relation to the values of the one-year old
host who is assumed to be non-imune. As infection frequency
changes over subsequent iterations of the model, the “immu-
nity profile” of the population is also allowed to change, an
“updating” that is made possible by adjusting the level of
immunity in the immunity function used in the model accord-
ing to the new transmission intensity.
Model inputs. The model requires the input of values for
key parameters. Where these are measurable these values are
taken from published data. However, where no data exists,
these values have been derived from field observations and
these assumptions are varied in the sensitivity analysis. The
key initial inputs to the model are as follows: 1) Population
size; 2) mutation rate or starting frequency of the mutation (1
in 109 to 1 in 1018); 3) initial level of resistance to the non-
artemisinin partner drug; 4) initial estimated EIR represent-
ing transmission intensity of the areas; 5) the basic reproduc-
tive rate (R0) of a non-treated, sensitive infection, which
ranges from 1 to 10; 6) the relative reproductive rates of
treated infections for sensitive infections and resistant infec-
FIGURE 2. Simplified model structure simulating one iteration
where immunity has been incorporated as a continuous factor. First,
the infected population is divided into resistant (R or res) and sen-
sitive (S or sens) infections. The proportion of infections that are
treated is determined by the level of immunity, which depends on the
transmission intensity. The proportion of infections treated with com-
bination therapy (CT) and monotherapy (not CT) is varied as an
input parameter. The reproductive rate (R0) varies according to type
of treatment and level of resistance and results in an increasing pro-
portion of resistant infections in the next iteration. The outputs of the
model are the predicted total number of malaria cases and the per-
centages of sensitive and resistant infections. nontreat non-treated.
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tions, which are all set in relation to this basic reproductive
rate. (There are few data on which to base these rates. How-
ever, it is assumed that the reproductive rate of a sensitive
infection that is treated with a non-artemisinin monotherapy
is twenty times less than the basic reproductive rate. If it is
treated with an artemisinin derivative, the reproductive rate is
assumed to be much less because artemisinins reduce the
parasite load much faster than other drugs and also prevent
gametocytogenesis. The reproductive rate of treated resistant
infections is assumed to be four times greater than treated
sensitive infections.37); 7) there is assumed to be no fitness
cost of carrying the resistant mutation. (This means that the
R0 is same for untreated infections whether they are sensitive
or resistant infections; 8) Maximum parasite density assumed
in a completely non-immune patient (109 to 1012 parasites per
person); 9) Maximum proportion of infected patients receiv-
ing any antimalarial (50−100%); 10) the ACT coverage rate,
i.e., proportion of antimalarial treatments received that are
ACT (0−100%).
Using the model to work out cost-effectiveness. The epide-
miologic model is then used as the basis for working out the
long-term cost-effectiveness of ACTs under different implemen-
tation conditions. Taking a societal perspective, costs to both
the patient and the provider are incorporated into the model.
Costs to the provider. One of the key concerns about using
ACTs has been the increased cost of drug, so the cost of initial
treatment with a first-line drug has been kept separate from
the cost of failure (which increase as more cases fail due to
increasing drug resistance). In addition to the cost of the an-
timalarial drug, the cost of the initial treatment to the public
provider includes the cost of consultation and diagnosis and
the inpatient costs for the small proportion of patients who
require hospitalization. The cost of failure includes the cost of
drugs that include second- and third-line drugs, the cost of
consultation and diagnosis, the cost of inpatient care, and the
cost of treating a number of specific complications such as
severe anemia, cerebral malaria, renal failure, and low birth
weight babies.
Cost to the patient. For patients attending public health fa-
cilities, the main costs are the direct costs of transport and
food. It is assumed that consultation, diagnosis, and treatment
are provided free. In reality, user fees are often charged, but
as this does not represent a net change in overall societal
costs; they are not included in the overall analysis and only
given separately where appropriate. For patients receiving
home treatment or attending informal sector providers for
modern medicines, the direct costs paid by the patient for
consultation, diagnosis, and treatment are included, as well as
the cost of transport and food.
In addition to the direct costs, the indirect impact on the
loss of productivity is estimated. This is presented both as
actual number of lost days of productivity as well as the cost
that this might represent. This is because of methodologic
difficulties in estimating the latter associated with the time of
year in relation to the agricultural calendar, family, and social
context, etc.
Each outcome state from the biologic model is assigned
likelihoods of cure and failure depending on level of resis-
tance and adherence. Since the actual cure rates of non-
adherers is unknown, estimates are derived using data from
drug efficacy trials that studied drug regimens with shorter du-
rations or lower drug doses than those currently recommended.
FIGURE 3. Different proportions of treated and non-treated patients in two extreme transmission intensity areas as determined by a binary
description of immunity (fully immune and non-immune). The proportion of infections that are treated, and therefore the selective advantage of
resistant infections, is greater in the low transmission settings. CT  combination therapy; Non-CT  non-combination therapy.
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Over the period of the analysis, e.g., 10 years, the number
of cases, cures, and failures and the total costs are summed.
By varying the input parameters, the effect of using different
drugs and drug combinations at different rates of coverage,
the costs and effectiveness in terms of cases and costs averted
can be compared. Furthermore, by incorporating the cost and
effectiveness of specific strategies that alter coverage or ad-
herence, the overall cost-effectiveness of changing drug policy
and of specific implementation strategies can be compared.
These could include pre-packaging drugs to increase adher-
ence or increasing the proportion of treated cases who first
have a definitive diagnosis.
DISCUSSION
Resistance to antimalarial drugs is resulting in avoidable
morbidity, mortality, and financial losses. Urgent measures
are needed now to reduce the current and future burden of
disease. There is little justification for the continued use of
ineffective drugs because effective drugs are currently avail-
able. The decisions of which drug regimen to change to, and
how to implement the change in a way that maximizes poten-
tial benefit, are more difficult, but delaying a decision to
switch because of these difficulties can only result in increased
morbidity and mortality. Furthermore, delaying a switch to
ACTs potentially puts at risk one of the key advantages of
this strategy, which is to delay the emergence of resistance.
The longer the decision is delayed, the more entrenched will
become the unregulated use of the artemisinins and partner
drugs as monotherapies. Partly because of the uncertainties,
there is still significant reluctance to take action amongst po-
tential funders and some national governments, both of
whose commitment is essential for the success of any change
in policy.
By developing a bioeconomic model that incorporates re-
alistic drug, parasite, host immunity, behavioral, and eco-
nomic factors, we hope to contribute a useful tool to this
debate. The model is currently being refined so that key re-
lationships are elucidated, particularly those relating to the
relationships between carrying a resistant genotype, adher-
ence to treatment, and outcome in terms of duration of illness
and cure. To clarify the importance of uncertainties and the
relative importance of such factors as coverage and adher-
ence, extensive sensitivity analysis is being undertaken. The
key objective is to produce a rational and transparent frame-
work that can be used as a tool for the planning and evalua-
tion of changes in drug policy and implementation strategies.
To this end, in addition to making extensive use of data from
the field in the model, we will be seeking to disseminate
widely the initial model and to encourage its adaptation and
application in different settings to maximize its robustness
and credibility. It is hoped that through this process, the
model will become a useful tool in supporting rational deci-
sion-making on the future deployment of ACT.
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